Skip to content

Amgen AMGN Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Roivant Sciences logo
Roivant SciencesROIV
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$195.44B+34.6%
Enterprise value$252.2B+25.7%
P/E25.1×+3.1×
P/S5.3×+1.1×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's accrued liabilities, current?
Amgen (AMGN) reported accrued liabilities, current of $16.58B in Q1 2026.
How has Amgen's accrued liabilities, current changed year-over-year?
Amgen's accrued liabilities, current decreased by 3.8% year-over-year, from $17.23B to $16.58B.
What is the long-term trend for Amgen's accrued liabilities, current?
Over 5 years (2020 to 2025), Amgen's accrued liabilities, current has grown at a 12.8% compound annual growth rate (CAGR), from $10.14B to $18.52B.